Board of Directors

Chairman of the Board since 2017

Catharina Bäärnhielm, PhD, born 1952

Catharina has a broad experience from a variety of senior positions in the pharmaceutical industry, most recently as VP/Global Project Director, at AstraZeneca. Her experience spans all phases of drug development, from idea to launch. She has extensive knowledge of running collaborations between industry and academia. Current positions include chairman of Cereno Scientific AB (listed at Spotlight), board member of GU Ventures AB and Senior Advisor to Karolinska Institutet.

Holding in the Company: 4 000 shares

Independence: Catharina is independent in relation to the Company and the Company’s largest owner

Founder and Board member since 2015

Kjell Olmarker, PhD, born 1958

With over 100 publications in the area of chronic back pain Kjell is considered one of the world’s most renowned researchers within the area. He holds a professorship at Gothenburg University and works actively in the development of the STA363 project, conducting a majority of the project’s in vivo studies and supporting the board in scientific matters.

Holding in the Company: 700 000 shares

Independence: Kjell is dependent in relation to the Company and the Company’s largest owner

Board member since 2018

Jane Buus Laursen, PhD, born 1975

Jane Buus Laursen is Corporate Vice President and head of Novo Nordisk’s Late Stage & Commercial Business Development. Before that, she spent 15 years at AstraZeneca where she completed a large number of deals with biotechs, pharma and academia spanning from early stage to late stage business transactions across all of AstraZeneca’s strategic areas. Her CV includes licensing deals, M&As, commercial partnerships and divestments of late stage clinical and on-market assets, in addition to spin-out of early stage assets.

Holding in the Company: 0 shares

Independence: Jane is independent in relation to the Company and the Company’s largest owner

Board member since 2016

Patrik Sjöstrand, BSc, born 1973

Patrik is investment manager at Almi Invest, Sweden’s most active venture capitalist investing. For the last 20 years, Patrik has worked predominantly in start-ups and smaller corporations as a project manager, managing director and chief operating officer. He also has 10 years of experience as a board member.

Holding in the Company: 0 shares

Independence: Patrik is independent in relation to the Company and dependent in relation to the Company’s largest owner

Board member since 2020

Erik Kinnman, PhD, MD, born 1958

Erik Kinnman has broad leadership experience and expertise from various assignments in the life science sector and many years of experience from leading positions in pharmaceutical companies such as AstraZeneca and Sobi. Erik’s expertise and experience encompass clinical development, business strategy, business development and investor relations, and he also has experience from the finance sector. He holds an Executive MBA degree from Stockholm School of Economics and extensive research qualifications from the Karolinska Institute where he received his PhD degree and Associate Professorship. Erik holds an MD degree with specialist expertise in neurology and pain relief. He is also the Managing Director of Abliva AB.

Holding in the Company: 0 shares

Independence: Erik is independent in relation to the Company and the Company’s largest owner